Corporate Profile

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions.

We believe EG-1962, our lead product candidate, can fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. Read More

Stock Information

EDGE (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$10.77
Change (%) Stock is Down 0.37 (0.00%)
Volume50,298
Data as of January 12, 2018 4:00 p.m. ET
Refresh quote

IR Contact

Gregory Gin
Email: ir@edgetherapeutics.com

Upcoming Events

There are currently no events scheduled.
More >>

Presentation

DateTitle
January 8, 2018
Download Documentation Investor Presentation – January 2017

Lastest News

December 29, 2017 - Edge's EG-1962 Phase 3 NEWTON 2 Study Continues as Planned Following Completion of Futility Analysis
Read More
November 6, 2017 - Edge Therapeutics to Present at the 26th Annual Credit Suisse Healthcare Conference
Read More
November 1, 2017 - Edge Therapeutics Reports Third Quarter 2017 Financial Results
Read More

More >>

Data provided by Nasdaq. Minimum 15 minutes delayed.

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR Contacts